Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy

Chinese Medical Journal

Volumn 118, Issue 7, 2005, Pages 555-560

  Zhang, Bo ^a,b   Liu, Zhi Hong ^a   Zeng, Cai Hong ^a   Zheng, Jing Min ^a   Chen, Hui Ping ^a   Zhou, Hong ^a   Li, Lei Shi ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apolipoprotein E; Genetic variation; Lipoprotein glomerulopathy

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL; CYCLOPHOSPHAMIDE; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN A; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNODIFFUSION; IMMUNOFLUORESCENCE; LIPODYSTROPHY; LIPOPROTEIN BLOOD LEVEL; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SCHOOL CHILD; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; CHILD; FEMALE; GENOTYPE; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; LIPOPROTEINS; MALE; MIDDLE AGED; VARIATION (GENETICS);

EID: 17144372589     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Saito T, Oikawa S, Sato H, et al. Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants. Nephron 1999;83:193-201.
2. Saito T, Ishigaki Y, Oikawa S, et al. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy. Trends Cardiovasc Med 2002;12:67-70.
3. Chen HP, Liu ZH, Gong RJ, et al. Clinical manifestations and pathological characteristics of lipoprotein glomerulopathy. Chin J Nephrol (Chin) 2002;18:403-407.
4. Oikawa S, Suzuki N, Sakuma E, et al. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis 1991;18:553-558.
5. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-1159.
6. Richard P, Thomas G, Pascual de Zulueta M, et al. Common and rare genotype of human apoprotein E determined by specific restriction profiles of polymerase chain reaction amplified DNA. Clin Chem 1994;40:24-29.
7. Gerdes LU. The common polymorphism of apolipoprotein E: geographical aspects and new pathophysiological relations. Clin Chem Lab Med 2003; 41:628-631.
8. Eto M, Horita K, Morikawa A, et al. Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (DIDDM) patients with nephropathy. Clin Genet 1995;48:288-292.
9. Ribalta J, Vallve JC, Girona J, et al. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr Opin Clin Nutr Metab Care 2003;6:177-187.
10. Yang AH, Ng YY, Tarng DC. Association of apolipoprotein E polymorphism with lipoprotein glomerulopathy. Nephron 1998;78:266-270.
11. Oda H, Yorioka N, Ueda C, et al. Apolipoprotein E polymorphism and renal disease. Kidney Int Suppl 1999;71:S25-S27.
12. Corbo RM, Vilardo T, Ruggeri M, et al. Apolipoprotein E genotype and plasma levels in coronary artery disease. A case-control study in the Italian population. Clin Biochem 1999;32:217-222.
13. Hoffmann M, Scharnagl H, Panagiotou E, et al. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol 2001;12:524-530.
14. Boren J, Olin K, Lee I, et al. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 1998;101:2658-2664.
15. Saito T, Oikawa S, Sato H, et al. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features. Kidney Int Suppl 1999;71:S37-S41.
16. Wen M, Segerer S, Dantas M, et al. Renal injury in apolipoprotein E-deficient mice. Lab Invest 2002;82: 999-1006.
17. Kanamaru Y, Nakao A, Shirato I, et al. Chronic graft-versus-host autoimmune disease in Fc Receptor γ chain-deficient mice results in lipoprotein glomerulopathy. J Am Soc Nephrol 2002;13:1527-1533.
18. Konishi K, Saruta T, Kuramochi S, et al. Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy. Nephron 1999;83:214-218.
19. Matsunaga A, Sasaki J, Komatsu T, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int 1999;56:421-427.
20. Oikawa S, Matsunaga A, Saito T, et al. Apolipoprotein E Sendai (Arginine 145→Proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol 1997;8:820-823.
21. Ogawa T, Maruyama K, Hattori H, et al. A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol 2000;14:149-151.
22. Ando M, Sasaki J, Hua H, et al. A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int 1999;56:1317-1323.
23. Murano T, Matsumura R, Misawa Y, et al. Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg25→Cys) from a patient with lipoprotein glomerulopathy. Metabolism 2002;51:201-205.
24. Ishigaki Y, Oikawa S, Suzuki T, et al. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem 2000;275:31269-31273.